# Intensity Therapeutics

Source: https://onco.cc/companies/intensity-therapeutics/  
OnCo record `intensity-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Intensity Therapeutics is a Connecticut biotech whose INT230-6 is injected straight into tumours with a penetration enhancer that spreads chemotherapy through the whole mass and triggers an immune response.

## Summary

Intensity Therapeutics developed INT230-6, an intratumoural formulation of cisplatin and vinblastine with the amphiphilic molecule SHAO, which disperses the drugs through the tumour and into cells. Killing the tumour in place releases antigens that prime systemic immunity. The company is running the phase 3 INVINCIBLE-3 trial in soft tissue sarcoma and the phase 2 INVINCIBLE-4 trial in presurgical triple-negative breast cancer.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Intensity Therapeutics, Inc.; NASDAQ:INTS
- Tags: drug-maker
- HQ: Shelton, Connecticut
- Type: biotech
- Website: https://www.intensitytherapeutics.com/
- Ticker: NASDAQ:INTS

## Sources

- Official website: https://www.intensitytherapeutics.com/

## Connected records

- drugs: [INT230-6](https://onco.cc/drugs/int230-6/)

---
JSON: https://onco.cc/api/v1/entities/intensity-therapeutics.json